OGN Organon & Co.
$13.76▲ +0.07%
Healthcare
Other
Volume 599.3K
Avg Volume (10D) 2.18M
Key Metrics & Fundamentals
Market Cap
$3.61B
P/E Ratio
17.6
Div Yield
0.58%
52W Range
5.69 - 13.83
% vs 50 MA
0.14%
% vs 200 MA
20.24%
RSI-14
52.7
MACD Histogram
+0.0000
Beta (1Y vs SPY)
0.79
Free Cash Flow
$31.00M
Gross Rev
$1.56B
Gross Profit
$847.00M
EBITDA
$374.00M
COGS
$711.00M
Operating Exp
$524.00M
Operating Income
$323.00M
EBIT
$323.00M
Pretax Income
$183.00M
Net Income
$108.00M
EPS (Diluted)
0.40
Price & Volume History
Loading chart…
Recent News
Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
GlobeNewswire · Oct 27, 2026 8:00 AM ET
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Zacks · Oct 26, 2026 8:00 AM ET
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Business Wire · Oct 19, 2026 7:30 AM ET
Organon Says 6-Year Miudella Data Supports FDA Application for Extended Use
MT Newswires · Oct 16, 2026 8:18 AM ET
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
Business Wire · Oct 16, 2026 7:30 AM ET
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks · Oct 14, 2026 8:00 AM ET
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Zacks · Oct 2, 2026 8:00 AM ET
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Business Wire · Oct 1, 2026 8:00 AM ET
Organon Says Nduvra Cream Gets Canada Approval for Atopic Dermatitis
MT Newswires · Sep 28, 2026 9:24 AM ET
Why Organon (OGN) Is Getting Attention Today
Simply Wall St. · Sep 22, 2026 8:15 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See OGN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.